2010 Update: Guidelines for the management of benign prostatic hyperplasia.
about
Microwave thermotherapy for benign prostatic hyperplasiaKorean clinical practice guideline for benign prostatic hyperplasiaA critical review of recent clinical practice guidelines on the diagnosis and treatment of non-neurogenic male lower urinary tract symptomsUpdate on medical therapy for male LUTSRandomized, controlled trial of laser vs. bipolar plasma vaporization treatment of benign prostatic hyperplasia.Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year rAssociation of Suicidality and Depression With 5α-Reductase Inhibitors.New clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms.Guideline for referral of patients with suspected prostate cancer by family physicians and other primary care providers.Systematic review of clinical features of suspected prostate cancer in primary care.Canadian trend in surgical management of benign prostatic hyperplasia and laser therapy from 2007-2008 to 2011-2012.Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?Assessment of photoselective vaporization of prostate skills during Urology Objective Structured Clinical Examinations (OSCE)Plasmakinetic resection technology for the treatment of benign prostatic hyperplasia: evidence from a systematic review and meta-analysis.Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis.Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia.Current status of 5α-reductase inhibitors in prostate disease managementManagement of large prostatic adenoma: Lasers versus bipolar transurethral resection of prostate.Cost analysis of fixed-dose combination of dutasteride and tamsulosin compared with concomitant dutasteride and tamsulosin monotherapy in patients with benign prostatic hyperplasia in Canada.Urological resident exposure to transurethral surgical options for BPH management in 2012-2013: A pan-Canadian survey.Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.Medical management of benign prostatic hyperplasia: Results from a population-based study.Lower urinary tract symptoms in a 66-year-old manThe association between the ICIQ-LUTS and the ICIQ-bladder diary in assessing LUTS.Urodynamics of men with urinary retention.The International Prostate Symptom Score (IPSS) Is an Inadequate Tool to Screen for Urethral Stricture Recurrence After Anterior Urethroplasty.Picking your prostates.Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers.The Modulating Effects of Benign Prostate Enlargement Medications on Upgrading Predictors in Patients with Gleason 6 at Biopsy.Cost-effectiveness of dutasteride-tamsulosin combination therapy for the treatment of symptomatic benign prostatic hyperplasia: A Canadian model based on the CombAT trial.Association between SRD5A2 rs523349 and rs9282858 Polymorphisms and Risk of Benign Prostatic Hyperplasia: A Meta-Analysis.Let's not forget about TUIP: A highly underutilized, minimally-invasive and durable technique for men with <30 g prostates.TURP in the new century: an analytical reappraisal in light of lasers.Management of lower urinary tract symptoms associated with benign prostatic hyperplasia in elderly patients with a new diagnostic, therapeutic and care pathway.Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the managePhotoselective vaporization of the prostate with the 180-W XPS-Greenlight laser: Five-year experience of safety, efficiency, and functional outcomes.A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride.Drugs for benign prostatic hypertrophy
P2860
Q24200487-82F763A1-4C9E-4B97-8DD1-638C06F8FC03Q26766302-B8C7EF08-66A6-4FFC-8C73-E18B0E7090C7Q26798012-6BF957C4-B940-40B3-87A3-4AFEDB80BE6AQ26862710-6413ADEF-A5CF-473F-9AA8-707E9C3363D2Q33803807-B682C27B-B97D-4091-8BC8-361F77CB710DQ34377799-F0F264AB-A83A-4F1D-8D65-F64A5A8F5914Q34553657-FF544D02-08D7-4EAB-BE09-4B32CE26ED70Q34635165-90E7BCF7-A660-4325-BE39-CB0AC2AF487AQ34994782-5437236B-3C74-49BC-8809-55FE017DDA3EQ34994815-327E9B38-0831-4D7C-AC47-EFC3DE869CF6Q34998408-38E5A6AB-D5AA-4FDF-92EF-8C02E4241DB2Q35050805-E5753B13-CA9C-4AD6-9084-0ED9524250DAQ35106388-CD0CEDD0-642A-4B08-A3BF-119B8826E01FQ35686476-316126F5-36B0-4C4B-BC2B-AD90977DDFE0Q35689075-96098BBF-AA6B-4D0C-A0F6-35BD7F43F563Q35989759-79DD9A9C-0D28-4BED-B71A-700F84C80EB6Q36778346-B2F055D3-06BF-4F96-BD8D-28DE37159303Q37198971-64848B44-EA1B-4FF3-BA3E-F059DC5B9694Q37496437-159967EC-B855-4728-8B5F-592586047452Q37593743-D2AAA616-8D16-4CD2-81A1-F069C3B04D4DQ37875062-658270F4-BDA1-46A7-99EC-799A9E595E17Q38682496-6BF35737-9081-430D-BD4B-6E3D46642EA2Q38747352-DD399EB7-4506-4946-A26D-05B856D2EE1AQ39236229-4A310527-0B20-4A3D-B5D3-8C066A0D74D7Q39421320-020664B8-7D1B-4CA8-8192-C8DE5650138BQ39826406-E07CFB64-A096-4C7E-9E82-C6C15766CA27Q40936371-8E5BE2F8-2843-4791-8DBB-23B3F859932EQ41092813-33E0B491-B974-41C9-BCA8-A7BFB02BDAE6Q41126233-FE47AB4D-B0ED-44B6-AF68-0BA2C5A19771Q41333008-B3A10C8A-F8AB-4148-A3A9-CB86A992BCEBQ41684535-1681AECF-9B3B-4952-ABEB-DB642A64799FQ41906222-EF516807-EBAD-48C4-8C99-1EB20F7CE72EQ42413456-B359B2C2-7778-4B4B-B564-7C3536D87BE5Q43353576-AC2D6AE5-64D3-43E4-84F3-EED892FC3EA4Q43902268-DED19146-3668-415D-AE86-A93733E0F4A3Q52617227-E5777E84-4ABE-4D85-8EBA-144110B197A0Q55380284-2684EE77-78DF-407C-852E-D4F8E8B4322FQ58588902-A84E2C40-ABD9-4C68-9A4D-E93B8D4C1AB9
P2860
2010 Update: Guidelines for the management of benign prostatic hyperplasia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
2010 Update: Guidelines for the management of benign prostatic hyperplasia.
@en
2010 Update: Guidelines for the management of benign prostatic hyperplasia.
@nl
type
label
2010 Update: Guidelines for the management of benign prostatic hyperplasia.
@en
2010 Update: Guidelines for the management of benign prostatic hyperplasia.
@nl
prefLabel
2010 Update: Guidelines for the management of benign prostatic hyperplasia.
@en
2010 Update: Guidelines for the management of benign prostatic hyperplasia.
@nl
P2093
P2860
P356
P1476
2010 Update: Guidelines for the management of benign prostatic hyperplasia.
@en
P2093
Carlos E Méndez-Probst
Hassan Razvi
J Curtis Nickel
Ryan F Paterson
Thomas F Whelan
P2860
P304
P356
10.5489/CUAJ.10124
P577
2010-10-01T00:00:00Z